课题基金 / 基金详情

项目摘要

项目成果

JOSHUA L DUNAIEF的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Project Summary / Abstract The Penn Vision Clinical Scientist Program (VCSP) is designed to prepare clinician scientists to identify and prioritize important questions in vision research, formulate a comprehensive approach to address the questions, and develop skills to effectively lead the efforts of a research team to provide answers. The (VCSP is centered in the Department of Ophthalmology, School of Medicine. Candidates for the VCSP hold a clinical doctoral degree (MD, PhD, DO, OD, DVM or equivalent) and have completed their clinical training, usually through the fellowship level. Scholars initially engage in educational and research activities to lay the groundwork for submission after 2 years of an application for an independent K08, K23, or R01. Scholars are supported on the K12 for up to 3 years, or until award of their individual grant, whichever comes first. Up to 2 scholars are supported on the K12 at any given time. The program takes advantage of established educational programs within the University, the concentration of strong basic science, translational research, and patient- oriented research programs ongoing within the Department of Ophthalmology, and the breadth of expertise available through Penn's interdisciplinary institutes and centers. Scholars have access to formal educational programs and applied research experiences in a vast array of areas such as clinical epidemiology, single-center and multi-center clinical trials, health services research, bioethics, genetics, molecular biology, and neuroscience. Established investigators in basic science, translational research, and patient-oriented research serve as mentors to guide choices by scholars in educational programs and research projects. The Penn VCSP has two defined tracks, translational research and patient oriented research. Each track has a didactic training component and a component of supervised research with increasing independence. However, the specific content of each program is custom built for each scholar. Each scholar has a primary mentor and a mentoring team to advise on the scientific aspects of their research and on activities necessary for professional development, collaboration among investigators, and developing long-term research programs. Upon completion of the program, scholars have received superb training to become productive and successful independent researchers.
期刊论文(50)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3389/fncel.2023.1156829
发表时间: 2023
期刊: Frontiers in cellular neuroscience
影响因子: 5.3
作者: []
通讯作者:
Diagnostic and therapeutic challenges.
诊断和治疗的挑战。
DOI: 10.1097/iae.0b013e3181a0bde9
发表时间: 2009
期刊: Retina (Philadelphia, Pa.)
影响因子: --
作者: [Yang,Sam, Borirakchanyavat,Sidhiporn, Chan-Kai,BrianT, Stout,JTimothy, Fu,ArthurD]
通讯作者: Fu,ArthurD
DOI: 10.3109/13816810.2015.1126616
发表时间: 2016-12
期刊: Ophthalmic genetics
影响因子: 1.2
作者: [Fuerst NM, Serrano L, Han G, Morgan JI, Maguire AM, Leroy BP, Kim BJ, Aleman TS]
通讯作者: Aleman TS
Rhizopus keratitis following corneal trauma.
角膜外伤后的根霉菌性角膜炎。
DOI: 10.1001/2013.jamaophthalmol.380
发表时间: 2013
期刊: JAMA ophthalmology
影响因子: 8.1
作者: [Azari,AmirA, Nehls,Sarah, Ghoghawala,ShahedY, Lee,Vivian, Kanavi,MozhganR, Potter,HeatherD]
通讯作者: Potter,HeatherD
25
    The IL-6 Induced Retinal Iron Sequestration Response
    • 批准号:
      10281696
    • 项目类别:
    • 资助金额:
      $40.6万
    • 财政年份:
      2019
    • 负责人:
      JOSHUA L DUNAIEF
    • 依托单位:
    The IL-6 Induced Retinal Iron Sequestration Response
    • 批准号:
      10416008
    • 项目类别:
    • 资助金额:
      $38.92万
    • 财政年份:
      2019
    • 负责人:
      JOSHUA L DUNAIEF
    • 依托单位:
    The IL-6 Induced Retinal Iron Sequestration Response
    • 批准号:
      10636913
    • 项目类别:
    • 资助金额:
      $40.12万
    • 财政年份:
      2019
    • 负责人:
      JOSHUA L DUNAIEF
    • 依托单位:
    Novel Iron Prochelators for Protection Against Oxidative Stress in RPE Cells
    • 批准号:
      7451925
    • 项目类别:
    • 资助金额:
      $24.95万
    • 财政年份:
      2008
    • 负责人:
      JOSHUA L DUNAIEF
    • 依托单位:
    海外基金